Corrigendum to "Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study" [Vaccine: X 11 (2022) 100189]
- PMID: 37131960
- PMCID: PMC10139920
- DOI: 10.1016/j.jvacx.2023.100307
Corrigendum to "Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study" [Vaccine: X 11 (2022) 100189]
Abstract
[This corrects the article DOI: 10.1016/j.jvacx.2022.100189.].
© 2023 The Author(s).
Erratum for
-
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study.Vaccine X. 2022 Aug;11:100189. doi: 10.1016/j.jvacx.2022.100189. Epub 2022 Jul 1. Vaccine X. 2022. PMID: 35791320 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources